top of page

Sutro Biopharma's CEO on ADCs, non-cell protein synthesis, and more

Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, designing therapies with non-cell protein synthesis, and Sutro’s numerous partnerships.



Comments


Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page